Legal & General Group Plc Sells 155,211 Shares of Elanco Animal Health Incorporated $ELAN

Legal & General Group Plc decreased its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 16.6% during the 4th quarter, HoldingsChannel.com reports. The fund owned 781,231 shares of the company’s stock after selling 155,211 shares during the period. Legal & General Group Plc’s holdings in Elanco Animal Health were worth $17,679,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in the stock. Hantz Financial Services Inc. raised its position in Elanco Animal Health by 227.5% in the fourth quarter. Hantz Financial Services Inc. now owns 12,561 shares of the company’s stock worth $284,000 after acquiring an additional 8,725 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new stake in shares of Elanco Animal Health in the fourth quarter valued at approximately $420,000. Coldstream Capital Management Inc. bought a new stake in shares of Elanco Animal Health in the fourth quarter valued at approximately $254,000. Jefferies Financial Group Inc. bought a new stake in shares of Elanco Animal Health in the fourth quarter valued at approximately $530,000. Finally, Global Retirement Partners LLC raised its position in shares of Elanco Animal Health by 385.7% in the fourth quarter. Global Retirement Partners LLC now owns 7,591 shares of the company’s stock valued at $172,000 after purchasing an additional 6,028 shares during the period. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Stock Performance

Elanco Animal Health stock opened at $23.70 on Tuesday. The firm’s 50 day simple moving average is $22.93 and its 200 day simple moving average is $23.33. The company has a current ratio of 2.16, a quick ratio of 1.12 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $11.84 billion, a PE ratio of -47.41, a price-to-earnings-growth ratio of 2.57 and a beta of 1.69. Elanco Animal Health Incorporated has a 1-year low of $13.09 and a 1-year high of $27.72.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.28 billion. During the same quarter in the prior year, the firm posted $0.37 EPS. Elanco Animal Health’s revenue was up 14.9% on a year-over-year basis. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, analysts expect that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Rajeev A. Modi purchased 4,911 shares of the business’s stock in a transaction on Friday, May 15th. The stock was acquired at an average price of $20.35 per share, with a total value of $99,938.85. Following the purchase, the insider directly owned 160,812 shares in the company, valued at approximately $3,272,524.20. This represents a 3.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Jeffrey N. Simmons purchased 4,971 shares of the business’s stock in a transaction on Friday, May 15th. The stock was bought at an average cost of $20.09 per share, with a total value of $99,867.39. Following the purchase, the chief executive officer owned 171,971 shares in the company, valued at approximately $3,454,897.39. This represents a 2.98% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 1.14% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. JPMorgan Chase & Co. boosted their price target on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Morgan Stanley boosted their price target on shares of Elanco Animal Health from $22.00 to $24.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 25th. Wall Street Zen lowered shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 24th. Citigroup boosted their price target on shares of Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Finally, Leerink Partners boosted their price target on shares of Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Tuesday, February 24th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Elanco Animal Health presently has an average rating of “Moderate Buy” and an average target price of $28.20.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.